| Name | Title | Contact Details |
|---|
CONNECT@College from Christie Campus Health helps colleges provide behavioral and mental health support for students, and logistical support for campus healthcare providers.
X4 Pharmaceuticals (Nasdaq: XFOR) is developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases, including primary immunodeficiencies and certain cancers. The company`s oral small molecule drug candidates antagonize the CXCR4 pathway, which plays a central role in immune surveillance. X4`s most advanced product candidate, mavorixafor (X4P-001), is in a global Phase 3 pivotal trial in patients with WHIM syndrome, a rare, inherited, primary immunodeficiency disease, and is currently also under investigation in combination with axitinib in the Phase 2a portion of an open-label Phase 1/2 clinical trial in clear cell renal cell carcinoma (ccRCC). X4 is also planning to commence clinical trials of mavorixafor in Severe Congenital Neutropenia (SCN) and Waldenström`s macroglobulinemia (WM) in 2019. The company was founded and is led by a team with extensive biopharmaceutical product development and commercialization expertise and is committed to advancing the development of innovative medicines on behalf of patients with limited treatment options. X4 is a global company that is headquartered in Cambridge, Massachusetts with research offices based in Vienna, Austria.
Clearside Biomedical, Inc. is a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat chronic, blinding diseases of the eye.
FloraWorks is a biotech enterprise that specializes in discovering rare and novel cannabinoids for commercial and therapeutic applications. They develop and patent scaled manufacturing pathways for cannabinoids with a high potential for therapeutic use...
Transtracheal Systems Inc is a Englewood, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.